Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Chemoimmunotherapy With Tislelizumab, Albumin-bound Paclitaxel, and Cisplatin in Locally Advanced Oral/Oropharyngeal Squamous Cell Carcinoma: A Prospective, Multicenter, Single-arm Study

NCT06009861 is registered in ClinicalTrials.gov with Peking University Hospital of Stomatology as lead sponsor.

NCT NCT06009861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06009861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Chemoimmunotherapy With Tislelizumab, Albumin-bound Paclitaxel, and Cisplatin in Locally Advanced Oral/Oropharyngeal Squamous Cell Carcinoma: A Prospective, Multicenter, Single-arm Study
Lead sponsor
Peking University Hospital of Stomatology
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 27, 2023
Completion date
June 30, 2027
Enrollment
110 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

oral squamous cell carcinoma, oropharyngeal squamous cell carcinoma